An Observational Study of MabThera in Participants With Severe Active Rheumatoid Arthritis

A Multicenter Observational Study of the Response to Rituximab (MabThera®) in Seropositive Patients With Rheumatoid Arthritis With Inadequate Response or Intolerance to Treatment With One or More Tumor Necrosis Factor Inhibitors (TNFi)

This observational study will evaluate the effect on disease activity and the safety in routine clinical practice of MabThera (rituximab) in participants with active seropositive rheumatoid arthritis, who have an inadequate response to one or more tumour necrosis factor inhibitor (anti-TNF) therapies.

Study Overview

• Status: Completed
• Conditions: Rheumatoid Arthritis
• Intervention / Treatment: Biological: Rituximab

• Study Type: Observational
• Enrollment (Actual): 135

Contacts and Locations

Study Locations

• Greece
  • Athens, Greece, 11521
  • Athens, Greece, 11527
  • Athens, Greece, 14527
  • Athens, Greece, 155 62
  • Haidari, Greece, 124 62
  • Herakleion, Greece, 71110
  • Ioannina, Greece, 455 00
  • Larissa, Greece, 411 10
  • Patra, Greece, 26335
  • Patras, Greece, 265 04
  • Thessaloniki, Greece, 546 42
  • Thessaloniki, Greece, 544 65
  • Thessaloniki, Greece, 57010
  • Voula, Greece, 16673

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Participants with severe active, seropositive rheumatoid arthritis who have an inadequate response or intolerance to anti-TNF therapy

Description

Inclusion Criteria:

• Age >18 years with rheumatoid arthritis (RA)
• Seropositive participants with RA (positive for rheumatoid factor (RF) and/or anti-Citrullinated Cyclic Peptide [CCP])
• Active disease despite receiving one or more TNF inhibitors
• Absence of serious or active infection

Exclusion Criteria:

• Participants with serious history of heart failure (class New York Heart Association [NYHA] IV) or severe uncontrolled heart disease
• Participants pregnant or lactating
• Prior treatment with Mabthera®
• Participants receiving any other investigational product in the context of other clinical study
• Participants with known hypersensitivity to rituximab or to any of the excipients

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Rituximab; Rituximab administered according to prescribing information and normal clinical practice.	Biological: Rituximab; Rituximab administered according to prescribing information and normal clinical practice.; Other Names: MabThera®

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Disease Activity Score Based on 28-joint Count and Erythrocyte Sedimentation Rate (DAS28-ESR) at Month 6 and Month 12	DAS28-ESR is a measure of the participant's disease activity and was calculated using the swollen joint count of 28 joints (SJC28), tender joint count of 28 joints (TJC28), erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and patient's global assessment of disease activity (100-millimeter [mm] horizontal visual analog scale with 0=no disease activity to 100=maximum disease activity). DAS28-ESR scores range from 0 to 10, with higher scores corresponding to greater disease activity.	Baseline, Month 6, Month 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants With European League Against Rheumatism (EULAR) Response at Month 6 and Month 12	EULAR response was calculated as the difference between DAS28-ESR scores at baseline and Month 6, and baseline and Month 12, and reported as the percentage of participants with response overall, good response, moderate response, and no response measured at each time point. Good responders = decrease from baseline >1.2 with a DAS28 score of ≤3.2; moderate responders = decrease from baseline >1.2 with a DAS28 score of >3.2, or decrease from baseline >0.6 to ≤1.2 with a DAS28 score of ≤5.1; non-responders = decrease from baseline ≤0.6 or decrease from baseline >0.6 and ≤1.2 with a DAS28 score of >5.1.	Baseline, Month 6, Month 12
Change From Baseline in Swollen Joint Count (SJC) at Month 6 and Month 12	SJC was determined by examining 28 and 66 joints and identifying when swelling was present. Swelling was recorded on the joint assessment form at baseline, no swelling = 0, swelling =1. The sum of swollen joints, each, ranged from 0 to 28 with 0 as best possible health status and 28 as worst health status. A decrease from baseline indicates improvement.	Baseline, Month 6, Month 12
Change From Baseline in Tender Joint Count (TJC) at Month 6 and Month 12	TJC was determined by examining 28 and 68 joints and identifying the joints that were painful under pressure or to passive motion. Tenderness was recorded on the joint assessment form at baseline, no tenderness = 0, tenderness = 1. A decrease from baseline indicates improvement.	Baseline, Month 6, Month 12
Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Month 6 and Month 12	ESR is an direct measure of how much inflammation is in the body. The normal range is 0-22 mm/hour for men and 0-29 mm/hour for women. A decrease from baseline indicates improvement.	Baseline, Month 6, Month 12
Change From Baseline in C-reactive Protein (CRP) at Month 6 and Month 12	C-reactive protein (CRP) is a blood test marker for inflammation in the body. Normal CRP levels are below 5.0 milligrams per liter (mg/L). A decrease from baseline indicates improvement.	Baseline, Month 6, Month 12
Percentage of Participants Who Remained on Treatment or Discontinued Treatment by Month 6 and Month 12		Up to 12 months
Reasons for Discontinuation of Treatment by Month 6	Reasons for discontinuation from baseline to Month 6 are presented as the number of participants who discontinued treatment by category of reason for discontinuation.	Baseline to Month 6
Reasons for Discontinuation of Treatment by Month 12	Reasons for discontinuation from baseline to Month 12 are presented as the number of participants who discontinued treatment by category of reason for discontinuation.	Baseline to Month 12
Percentage of Participants With Clinically Meaningful Improvement From Baseline in Modified Health Assessment Questionnaire (M-HAQ)	The M-HAQ is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. A negative change from baseline indicates improvement. Clinically meaningful improvement was defined as minimum clinically significant reduction from baseline of ≥0.22 at the respective time point.	Up to 12 months
Percentage of Participants With Adverse Events (AEs) and Adverse Drug Reactions (ADRs)	An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An ADR was defined as any noxious and unintended response to a medicinal product related to any dose. AEs of special interest includes progressive multifocal leukoencephalopathy (PML), any encephalopathy, hepatitis B or hepatitis B reactivation, gastrointestinal perforation, tuberculosis (TB) or TB reactivation, opportunistic infections, and malignancies.	Up to 12 months
Percentage of Participants With Any Non-Serious AE and Any Serious AE by Intensity	Percentage of participants with any non-serious AE and any serious AE by intensity (mild, moderate, severe) was reported. An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.	Up to 12 months
Percentage of Non-Serious AEs	Percentage of non-serious AEs resolved and ongoing at the time of study completion were reported. An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.	Up to 12 months
Percentage of Non-Serious ADRs	Percentage of non-serious ADRs at the time of study completion was reported. An ADR was defined as any noxious and unintended response to a medicinal product related to any dose.	Up to 12 months
Percentage of Serious AEs	Percentage of serious AEs resolved and ongoing at the time of study completion was reported. An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.	Up to 12 months
Percentage of Serious ADRs	Percentage of serious ADRs resolved and ongoing at the time of study completion was reported. An ADR was defined as any noxious and unintended response to a medicinal product related to any dose.	Up to 12 months

Collaborators and Investigators

• Sponsor: Hoffmann-La Roche

Study record dates

Study Major Dates

• Study Start: February 1, 2012
• Primary Completion (Actual): September 1, 2015
• Study Completion (Actual): September 1, 2015

Study Registration Dates

• First Submitted: May 25, 2012
• First Submitted That Met QC Criteria: June 4, 2012
• First Posted (Estimate): June 6, 2012

Study Record Updates

• Last Update Posted (Estimate): October 24, 2016
• Last Update Submitted That Met QC Criteria: August 31, 2016
• Last Verified: August 1, 2016

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Autoimmune Diseases; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Arthritis; Arthritis, Rheumatoid; Physiological Effects of Drugs; Antirheumatic Agents; Antineoplastic Agents; Immunologic Factors; Antineoplastic Agents, Immunological; Rituximab
• Other Study ID Numbers: ML27998